Gram-negative bacteremia: Which empirical antibiotic therapy?

Given the increasing frequency of cefotaxime-resistant strains, third-generation cephalosporins (3GC e.g. cefotaxime, ceftriaxone) might not be recommended any longer as empirical antibiotic therapy for community-acquired Gram-negative bacteremia (CA-GNB). We conducted a multicenter prospective desc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Médecine et maladies infectieuses 2014-04, Vol.44 (4), p.159-166
Hauptverfasser:	Shoai Tehrani, M., Hajage, D., Fihman, V., Tankovic, J., Cau, S., Day, N., Visseaux, C., Carbonnelle, E., Kouatchet, A., Cattoir, V., Nhan, T.X., Corvec, S., Jacquier, H., Jauréguy, F., Le Monnier, A., Morand, P., Zahar, J.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteremia - drug therapy Bacterial diseases Bacterial sepsis Bactériémie à Gram négatif Biological and medical sciences Bêta-lactamase à spectre étendu Cefotaxime-resistance Cephalosporin Resistance Community-Acquired Infections - drug therapy Enterobacteriaceae Escherichia coli Extended-spectrum b-lactamase Gram-negative bacteremia Gram-Negative Bacterial Infections - drug therapy Health care-associated infection Human bacterial diseases Humans Infectious diseases Medical sciences Pharmacology. Drug treatments Prospective Studies Pseudomonas aeruginosa Résistance au céfotaxime
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!